From Adaptive Licensing to Adaptive Pathways: Delivering a Flexible Life-Span Approach to Bring New Drugs to Patients

Published on Mar 1, 2015in Clinical Pharmacology & Therapeutics6.336
· DOI :10.1002/cpt.59
H G Eichler8
Estimated H-index: 8
(European Medicines Agency),
Lynn G. Baird5
Estimated H-index: 5
(MIT: Massachusetts Institute of Technology)
+ 38 AuthorsGigi Hirsch7
Estimated H-index: 7
(MIT: Massachusetts Institute of Technology)
The concept ofadaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name ofAL should be broadened.Against this background of ongoing debate, we examine the environmental changes that will likely make adaptive pathways the preferred approach in the future.The key drivers include: growing patient demand for timely access to promising therapies, emerging scienceleading to fragmentation of treatmentpopulations, rising payer influence on product accessibility, and pressure on pharma/investors to ensure sustainability of drugdevelopment. We also discuss a numberof environmental changes that will enable an adaptive paradigm.A life-span approach to bringing innovation to patients is expected to help address the perceived access vs. evidence trade-off, help de-risk drug development, and lead to better outcomes for patients.
  • References (40)
  • Citations (115)
📖 Papers frequently viewed together
206 Citations
54 Citations
156 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Niels S. Vermeer (UU: Utrecht University)H-Index: 6
#2Ruben G. Duijnhoven (UU: Utrecht University)H-Index: 7
Last. M L De Bruin (UU: Utrecht University)H-Index: 14
view all 8 authors...
Risk Management Plans (RMPs) have become a cornerstone in the pharmacovigilance of new drugs in Europe. The RMP was introduced in 2005 to support a proactive approach in gaining knowledge on safety concerns through early planning of pharmacovigilance activities. However, the rate at which uncertainties in the safety profile are resolved through this proactive approach is unknown. We therefore examined the evolution of safety concerns in the RMP after initial approval for a selected cohort of 48 ...
18 CitationsSource
#1Lynn G. Baird (MIT: Massachusetts Institute of Technology)H-Index: 5
#2R. BankenH-Index: 1
Last. Gigi Hirsch (MIT: Massachusetts Institute of Technology)H-Index: 7
view all 14 authors...
54 CitationsSource
Economic evaluation of end of life care is increasingly expected from both research funders and those making decisions about the use of health and social care resources. There are, however, difficulties in applying the currently established evaluative methods to end of life. These are partly associated with the sensitivity of the topic and the feasibility of data collection but also, more fundamentally, a lack of agreement about the terms in which such care should be evaluated. This paper examin...
33 CitationsSource
#1Rachael L. Fleurence (Patient-Centered Outcomes Research Institute)H-Index: 21
#2Lesley H. Curtis (Duke University)H-Index: 56
Last. Jeffrey S. Brown (Harvard University)H-Index: 34
view all 6 authors...
The Patient-Centered Outcomes Research Institute (PCORI) has launched PCORnet, a major initiative to support an effective, sustainable national research infrastructure that will advance the use of electronic health data in comparative effectiveness research (CER) and other types of research. In December 2013, PCORI’s board of governors funded 11 clinical data research networks (CDRNs) and 18 patient-powered research networks (PPRNs) for a period of 18 months. CDRNs are based on the electronic he...
204 CitationsSource
#1Don Husereau (U of O: University of Ottawa)H-Index: 21
#2Chris Henshall (Brunel University London)H-Index: 8
Last. Jamil JivrajH-Index: 1
view all 3 authors...
Background: Adaptive approaches to the introduction of drugs and medical devices involve the use of an evolving evidence base rather than conventional single-point-in-time evaluations as a proposed means to promote patient access to innovation, reduce clinical uncertainty, ensure effectiveness, and improve the health technology development process. Methods: This report summarizes a Health Technology Assessment International (HTAi) Policy Forum discussion, drawing on presentations from invited ex...
14 CitationsSource
Canada’s House of Commons has granted the health ministry sweeping new powers to remove drugs from the market and punish manufacturers who sell dangerous drugs or withhold information on adverse effects. Until now, the Canadian government has relied on voluntary agreements with manufacturers to remove dangerous medicines from the market, a system that broke down most notoriously in 1962 when a special act of parliament was needed to remove thalidomide from the Canadian market long after the US F...
1 CitationsSource
#1Paolo Bianco (Sapienza University of Rome)H-Index: 70
#2Douglas SippH-Index: 20
Stem cells are being used as a wedge in calls to allow unproven medical interventions onto the market, warn Paolo Bianco and Douglas Sipp.
40 CitationsSource
#1Bruce M. Psaty (UW: University of Washington)H-Index: 154
#2Alasdair Breckenridge (University of Liverpool)H-Index: 51
Under the leadership of the FDA and study investigators, the Mini-Sentinel project has not only transformed big medical data into a national research resource fit for purpose, but also created a co...
61 CitationsSource
Two key applications of big health care data are generating knowledge about treatment effectiveness and predicting outcomes. Though the analytic tools exist, our health care system hasn't been able to use them to create an ongoing learning-and-improvement process.
188 CitationsSource
Current European pharmaceutical legislation is not adequate to meet advances in science and technologies that will lead to rapid development of custom-made medicines. Using existing legislation for custom-made medical devices as a template and anti-sense oligonucleotides as model medicinal products, we propose new European pharmaceutical legislation to permit timely access to custom-made anti-sense oligonucleotide medicinal products. The proposals may be more widely applicable to other medicinal...
4 CitationsSource
Cited By115
#1Tingting Qiu (AMU: Aix-Marseille University)H-Index: 1
#2E HannaH-Index: 3
Last. Mondher Toumi (AMU: Aix-Marseille University)H-Index: 12
view all 5 authors...
Abstract Background A small number of regenerative medicines (RMs) have received market authorization (MA) worldwide, relative to the large number of clinical trials currently being conducted. Regulatory issues constitute one major challenge for the MA of RMs. Objective This study aimed to systematically review the regulation of RMs internationally, to identify the regulatory pathways for approved RMs, and to detail expedited programs to stimulate MA process. Methods Official websites of regulat...
#1Mohamed Amine Bayar (Université Paris-Saclay)H-Index: 6
#2Gwénaël Le Teuff (Université Paris-Saclay)H-Index: 17
Last. Stefan Michiels (Université Paris-Saclay)H-Index: 52
view all 5 authors...
In rare diseases, fully powered large trials may not be doable in a reasonable time frame even with international collaborations. In a previous work, we proposed an approach based on a series of sm...
Last. Joseph Kim (UCL: University College London)H-Index: 1
view all 5 authors...
: Several approaches have been proposed recently to accelerate the pathway from drug discovery to patient access. These include novel designs such as using controls external to the clinical trial where standard randomised controls are not feasible. In parallel, there has been rapid growth in the application of routinely collected healthcare 'real-world' data for post-market safety and effectiveness studies. Thus, using real-world data to establish an external comparator arm in clinical trials is...
#1Valentina Cisnetto (Imperial College London)H-Index: 1
#2James Barlow (Imperial College London)H-Index: 37
Abstract When there is significant uncertainty in an innovation project, research literature suggests that strictly sequencing actions and stages may not be an appropriate mode of project management. We use a longitudinal process approach and qualitative system dynamics modelling to study the development of genetically modified (GM) mosquitoes for malaria eradication in an African country. Our data were collected in real time, from early scientific research to deployment of the first prototype m...
2 CitationsSource
#1Rick A. Vreman (UU: Utrecht University)H-Index: 3
#2Huseyin Naci (LSE: London School of Economics and Political Science)H-Index: 24
Last. Aaron S. Kesselheim (Brigham and Women's Hospital)H-Index: 44
view all 7 authors...
Assessments of clinical evidence vary between regulators and health technology assessment bodies, but precise differences remain unclear. To compare uncertainties raised on the clinical evidence of approved drugs, we analyzed assessments of regulators and health technology assessment (HTA) bodies in the US and Europe. We found that US and European regulators report uncertainties related to safety for almost all drugs (85-94%) whereas HTA bodies reported these less (53-59%). By contrast, HTA bodi...
#1Robbe Saesen (Katholieke Universiteit Leuven)H-Index: 1
#2Stéphane Lejeune (European Organisation for Research and Treatment of Cancer)H-Index: 13
Last. Isabelle Huys (Katholieke Universiteit Leuven)H-Index: 24
view all 5 authors...
Background: The current drug development paradigm has been criticized for being too drug-centered and for not adequately focusing on the patients that will eventually be administered the therapeutic interventions it generates. The drug-driven nature of the present framework has led to the emergence of a research gap between the pre-approval development of anticancer medicines and their post-registration use in real-life clinical practice. This gap could potentially be bridged by transitioning to...
1 CitationsSource
#2Ash Bullement (University of Nottingham)H-Index: 4
Last. Mark Strong (University of Sheffield)
view all 5 authors...
Abstract Background Changes in the regulatory context enable faster approval of transformative medicines. They also lead to health technology assessment (HTA) agencies having to make decisions with less evidence. In response, HTA agencies have also initiated forms of conditional approval. When the evidence base for a new oncology treatment leaves substantial uncertainty, the new Cancer Drugs Fund allows the National Institute for Heath and Care Excellence to give the manufacturer two options: (1...
#1Tine Geldof (Katholieke Universiteit Leuven)H-Index: 1
#2Nancy Van DammeH-Index: 1
Last. Walter Van Dyck (Katholieke Universiteit Leuven)H-Index: 2
view all 4 authors...
Objectives: Little research has been done in pharmacoepidemiology on the use of machine learning for exploring medicinal treatment effectiveness in oncology. Therefore, the aim of this study was to explore the added value of machine learning methods to investigate individual treatment responses for glioblastoma patients treated with temozolomide. Methods: Based on a retrospective observational registry covering 3090 patients with glioblastoma treated with temozolomide, we proposed the use of a t...
1 CitationsSource
#1J.W. Geenen (UU: Utrecht University)H-Index: 2
#2Mark Jut (UU: Utrecht University)H-Index: 1
Last. Anke M. Hövels (UU: Utrecht University)H-Index: 10
view all 5 authors...
ABSTRACTBackground: In many countries, Budget Impact (BI) informs reimbursement decisions. Evidence has shown that decision-makers have restricted access based on high BI estimates but studies show...
1 CitationsSource
#1Luca Pani (University of Modena and Reggio Emilia)H-Index: 39
#2Richard S.E. Keefe (Duke University)H-Index: 83
1 CitationsSource